<DOC>
	<DOCNO>NCT00020358</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Vaccine therapy may effective treatment melanoma . PURPOSE : Randomized phase II trial study effectiveness three vaccine therapy regimens treat patient melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare immunologic activity three different schedule peptide immunization gp100:209-217 ( 210M ) gp100:17-25 antigen tyrosinase:368-376 ( 370D ) , tyrosinase:240-251 ( 244S ) , tyrosinase:206-214 ( closed accrual 11/05/01 ) , tyrosinase-related protein-1 ( ORF3 ) :1-9 peptide ( close accrual 11/05/01 ) emulsify Montanide ISA-51 patient melanoma high risk recurrence . - Compare response rate treatment interleukin-2 ( IL-2 ) immunize regimen usual response rate IL-2 patient population . - Determine whether exploratory cohort HLA-A2-positive patient demonstrate immunologic activity immunization 2 peptide emulsify together . OUTLINE : This randomize study . Patients stratify accord HLA type ( A0201 vs A1 v A3 v A24 v A31 ) . ( HLA-A24 HLA-A31 close accrual 11/05/01 ) . Patients randomize 1 3 treatment arm give assigned vaccine , emulsify Montanide ISA-51 . - HLA typing : - HLA-A2 : gp100:209-217 ( 210M ) tyrosinase:368-376 ( 370D ) - HLA-A1 : tyrosinase:240-251 ( 244S ) - HLA-A3 : gp100:17-25 - HLA-A24 : tyrosinase:206-214 ( closed accrual 11/05/01 ) - HLA-A31 : tyrosinase-related protein-1 ( ORF3 ) :1-9 ( closed accrual 11/05/01 ) - Arm I : Patients receive assign vaccine subcutaneously ( SC ) weekly 10 week follow 3 week treatment . - Arm II : Patients receive assign vaccine SC day 1 , 22 , 43 , 64 . - Arm III : Patients receive assign vaccine SC day 1-4 , 22-25 , 43-46 , 64-67 . Treatment arm repeat every 13 week 4 course absence disease progression unacceptable toxicity . After completion randomize arm HLA-A2 patient , additional HLA-A2 patient receive immunization gp100:209-217 ( 210M ) tyrosinase:368-376 ( 370D ) emulsify Montanide ISA-51 SC every 3 week 4 course . Patients progressive disease may receive interleukin-2 IV 15 minute every 8 hour 4 day . Treatment repeat every 10-14 day least 4 course absence disease progression unacceptable toxicity . Patients stable disease mixed partial response treatment may receive additional course every 2 month . Patients follow 6 month . PROJECTED ACCRUAL : A total 324 patient ( 19-33 per arm HLA-A0201 stratum , 13-16 per arm 4 stratum , 33 per additional HLA-A2 cohort ) accrue study within 2 year . ( HLA-A24 HLA-A31 close accrual 11/05/01 ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis melanoma , include one follow characteristic : Lesions least 1.5 mm thickness At least 1 positive lymph node Ulcerated lesion Local recurrence Metastatic lesion completely resect within past 6 month Clinically disease free within past 6 week HLAA1 , A3 , A24 , A31 , 0201 positive ( HLAA24 HLAA31 close accrual 11/05/01 ) No ocular mucosal melanoma PATIENT CHARACTERISTICS : Age : 16 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 90,000/mm^3 Hepatic : Bilirubin great 1.6 mg/dL ( 3.0 mg/dL Gilbert 's syndrome ) AST ALT less 3 time normal Hepatitis B surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : For interleukin2 ( IL2 ) therapy : No cardiac ischemia , myocardial infarction , cardiac arrhythmia Stress cardiac test require abnormal EKG , symptom cardiac ischemia arrhythmia , old 50 year Pulmonary : For IL2 therapy : No obstructive restrictive pulmonary disease FEV_1 great 60 % predict prolonged history cigarette smoking symptom respiratory dysfunction Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception HIV negative No active systemic infection , autoimmune disease , active primary secondary immunodeficiency PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior systemic biologic therapy melanoma No prior gp100 antigen tyrosinase TRP1 peptide No concurrent systemic biologic therapy melanoma Chemotherapy : At least 3 week since prior systemic chemotherapy recover No concurrent systemic chemotherapy melanoma Endocrine therapy : At least 3 week since prior systemic endocrine therapy melanoma No concurrent systemic steroid therapy Radiotherapy : At least 3 week since prior systemic radiotherapy recover No concurrent systemic radiotherapy melanoma Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>stage I melanoma</keyword>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>